Investors in Plus Therapeutics, Inc. (NASDAQ:PSTV) may take interest in the recent insider trading activity reported by Director Richard J. Hawkins (NASDAQ:HWKN). On September 13, 2024, Hawkins acquired 4,000 shares of the company's common stock, totaling an investment of approximately $6,000.
The transaction took place at a weighted average price of $1.499 per share, with individual sales occurring at prices ranging from $1.47 to $1.50. Following this purchase, Hawkins now owns a total of 15,188 shares in Plus Therapeutics.
The disclosed transactions suggest a vote of confidence from the director in the company's prospects. Plus Therapeutics, known for its work in the medical instruments and apparatus industry, continues to be a point of focus for investors tracking insider trading patterns for insights into company performance and director sentiment.
The details of the transaction were made available in a recent filing with the Securities and Exchange Commission, providing transparency into the trading activities of company insiders. Shareholders and potential investors can access full information about the volume of shares acquired at each price point within the reported range upon request.
Plus Therapeutics, previously known as Cytori Therapeutics and Macropore Inc., is based in Austin, Texas, and specializes in the development of innovative treatments in the medical field. The company's stock trades on the NASDAQ exchange under the ticker symbol PSTV.
In other recent news, Plus Therapeutics, a medical device company, is facing potential delisting from the Nasdaq Stock Market due to an equity shortfall. The company failed to meet the minimum stockholders' equity requirement for continued listing, despite submitting a plan to regain compliance. Plus Therapeutics intends to appeal this determination, pausing any suspension or delisting action until the Hearings Panel's decision.
In financial updates, Plus Therapeutics reported a Q2 revenue of $1.3 million, which fell short of the anticipated $1.6 to $1.7 million range. This led Ascendiant Capital to revise its 2024 revenue estimates for the company from $7 million to $5 million. The company also reported an EPS of $(0.71), with a net loss of $7.6 million, not aligned with the estimated $(0.37) and consensus of $(0.53).
In other company developments, Plus Therapeutics shareholders elected six members to the Board of Directors and approved the fourth amendment and restatement of the company's 2020 Stock Incentive Plan. Furthermore, the company secured a $3 million award from the U.S. Department of Defense for a pediatric brain cancer trial and plans to complete enrollment for a potential pivotal trial by the end of 2024 or early 2025. These are the latest developments for Plus Therapeutics.
InvestingPro Insights
Following the insider trading activity by Director Richard J. Hawkins at Plus Therapeutics, Inc. (NASDAQ:PSTV), investors may be curious about the company's financial health and market performance. According to recent data from InvestingPro, Plus Therapeutics holds a market capitalization of $8.9 million. Despite a significant revenue growth of 113.2% in the last twelve months as of Q2 2024, the company struggles with profitability, marked by a negative P/E ratio of -0.67 and a gross profit margin of -96.46%.
InvestingPro Tips highlight that Plus Therapeutics is quickly burning through cash and has short-term obligations exceeding its liquid assets. Analysts have also revised their earnings downwards for the upcoming period, indicating potential concerns about the company's future performance. Moreover, the company does not pay a dividend to shareholders, which might be a consideration for investors seeking income-generating investments.
Despite these challenges, the company experienced a notable return over the last week, with a 17.46% price total return. This could signal a positive short-term sentiment among some investors, as evidenced by the insider purchase by Director Hawkins. For investors looking for deeper insights, there are 10 additional InvestingPro Tips available, which can be accessed to better understand the intricacies of Plus Therapeutics' financial position and market performance.
As Plus Therapeutics continues to navigate the competitive landscape of the medical instruments and apparatus industry, staying informed with the latest data and expert analysis will be crucial for investors. The InvestingPro platform offers a comprehensive view of the company's metrics, including the InvestingPro Fair Value estimate of $2.02, which can help in making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.